AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 21.5 |
Market Cap | 1.69B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.09 |
PE Ratio (ttm) | -243.44 |
Forward PE | n/a |
Analyst | Sell |
Ask | 22 |
Volume | 238,944 |
Avg. Volume (20D) | 760,490 |
Open | 22.33 |
Previous Close | 22.29 |
Day's Range | 21.27 - 22.56 |
52-Week Range | 16.81 - 45.42 |
Beta | undefined |
About IART
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracrani...
Analyst Forecast
According to 7 analyst ratings, the average rating for IART stock is "Sell." The 12-month stock price forecast is $22, which is an increase of 0.41% from the latest price.
Next Earnings Release
Analysts project revenue of $445.15M, reflecting a 12.12% YoY growth and earnings per share of 0.85, making a -4.49% decrease YoY.
2 months ago · seekingalpha.com
Integra LifeSciences Holdings Corporation (IART) Q3 2024 Earnings Call TranscriptIntegra LifeSciences Holdings Corporation (NASDAQ:IART ) Q3 2024 Earnings Call Transcript November 4, 2024 8:30 AM ET Company Participants Chris Ward - IR Stuart Essig - Executive Chairman Jan De Witt...